AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLINUVEL PHARMACEUTICALS LTD

8.010

-0.150-1.84%

Volume:180.47K

Turnover:1.45M

Market Cap:402.11M

PE:11.99

High:8.260

Open:8.170

Low:7.950

Close:8.160

52wk High:13.399

52wk Low:7.950

Shares:50.20M

Float Shares:41.32M

Volume Ratio:1.91

T/O Rate:0.44%

Dividend:0.05

Dividend Rate:0.62%

EPS(TTM):0.668

EPS(LYR):0.668

ROE:13.21%

ROA:8.94%

PB:1.47

PE(LYR):11.99

Loading ...

Overview Company News Filings

Clinuvel Pharmaceuticals Completes Development of Proprietary Drug Delivery Device

MT Newswires Live

Spotlight for Clinuvel Turning to Vitiligo Trial Readout

Clinuvel Pharmaceuticals (ASX:CUV) Shares Undervalued Or Warning On Single Drug Risk?

Simply Wall St.

Morgans Financial Downgrades Clinuvel Pharmaceuticals to Hold from Speculative Buy; Price Target is AU$10

MT Newswires Live

Clinuvel Pharmaceuticals Ltd FY Basic EPS AUD 0.68

THOMSON REUTERS

Press Release: a Decade of Profitability Provides Foundation for CLINUVEL's U.S. Expansion

Clinuvel Board Mulls Change to Group Structure, Potential Nasdaq Listing, ASX Delisting; Shares Dive 9%

MT Newswires Live

Clinuvel Pharmaceuticals Fiscal 2026 Earnings, Revenue Down

MT Newswires Live

Clinuvel Posts Fy2026 Net Profit After Tax of A$34 Million, Cash Reserves Rise to A$252 Million

Clinuvel Pharmaceuticals - to Relocate Operational Headquarters to United States

THOMSON REUTERS

Clinuvel Pharmaceuticals - Deal Subject to Shareholder and Court Approval

THOMSON REUTERS

Clinuvel Pharmaceuticals - Shareholders to Receive Equivalent Economic Interest in NASDAQ Listed Company

THOMSON REUTERS

Clinuvel Pharmaceuticals - Final Board Decision on Deal Pending; Due Diligence Ongoing

THOMSON REUTERS

Clinuvel Pharmaceuticals Ltd-Clinuvel Considers NASDAQ Listing, ASX Delisting

THOMSON REUTERS

Clinuvel Pharmaceuticals Annual Franked Dividend of A$0.05 Per Ordinary Share

THOMSON REUTERS

Clinuvel Schedules Annual Results Investor Webinar

Clinuvel Plans Additional Preclinical Study of VLRX-L Controlled-Release Peptide Platform in Q1 2027

Clinuvel Pharmaceuticals Identifies High-Potential Dose Formulations for Injectable Peptide Platform

MT Newswires Live

Clinuvel Pharmaceuticals Strengthens Supply Chain as Part of Commercial Preparations for North American Vitiligo Market

MT Newswires Live

Clinuvel Benchmarks Vitiligo Market as JAK Inhibitor Efficacy Challenges Nb-uvb Standard of Care

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/CUV.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CUV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","market":"AU","secType":"STK","nameCN":"CLINUVEL PHARMACEUTICALS LTD","latestPrice":8.01,"timestamp":1789020720000,"preClose":8.16,"halted":0,"volume":180467,"delay":0,"changeRate":-0.018382352941176513,"nameEN":"CLINUVEL PHARMACEUTICALS LTD","floatShares":41318955,"shares":50200740,"eps":0.667999,"marketStatus":"Closed","change":-0.15,"latestTime":"09-10 16:12:00 AEST","open":8.17,"high":8.26,"low":7.95,"amount":1450513,"amplitude":0.03799,"askPrice":8.1,"askSize":535,"bidPrice":8,"bidSize":732,"shortable":3,"etf":0,"ttmEps":0.667999,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":8.16,"dividendRate":0.006242,"openAndCloseTimeList":[[1788998400000,1789020000000]],"volumeRatio":1.910796,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CUV.AU","preClose":8.16,"auctionPrice":8.01,"auctionVolume":9316,"auctionTime":1789020604080,"referencePrice":8.01,"referenceTime":1789030800651,"auction":3,"marketStatus":"盘后竞价","timestamp":1789020604080}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","floatShares":41318955,"roa":"8.94%","roe":"13.21%","lyrEps":0.667999,"volumeRatio":1.910796,"shares":50200740,"dividePrice":0.05,"high":8.26,"amplitude":0.03799,"preClose":8.16,"low":7.95,"week52Low":7.95,"pbRate":"1.47","psRate":"4.28","week52High":13.399,"institutionHeld":0,"latestPrice":8.01,"committee":0.155485,"eps":0.667999,"divideRate":0.006242,"volume":180467,"delay":0,"ttmEps":0.667999,"open":8.17,"prevYearClose":12.385,"prevWeekClose":8.15,"prevMonthClose":7.972,"prevQuarterClose":10.219,"fiveDayClose":8.26,"twentyDayClose":9.533,"sixtyDayClose":9.871,"dividendPayoutRate":0.07372445631899688,"dividendFrequency":"A","dividendGrowthYears":6,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.0033959070154716284},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CUV.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-03","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-04","defaultRemindTime":1788393600000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-18","payableDate":"2026-09-04","currency":"AUD","dateTimestamp":1788357600000,"payDate":"2026-09-18"},{"date":"2026-08-27","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1772060400000,"name":null,"time":"","dateTimestamp":1772024400000,"actualEps":null},{"date":"2025-09-04","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-05","defaultRemindTime":1756944000000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-05","currency":"AUD","dateTimestamp":1756908000000,"payDate":"2025-09-19"},{"date":"2025-08-28","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756339200000,"name":null,"time":"","dateTimestamp":1756303200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CUV.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-03","recordDate":"2020-09-04","paymentDate":"2020-09-18","value":0.025,"currency":"AUD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-17","value":0.025,"currency":"AUD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-09-21","value":0.04,"currency":"AUD"},{"executeDate":"2023-09-05","recordDate":"2023-09-06","paymentDate":"2023-09-20","value":0.05,"currency":"AUD"},{"executeDate":"2024-09-05","recordDate":"2024-09-06","paymentDate":"2024-09-20","value":0.05,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CUV.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665334536","title":"Clinuvel Pharmaceuticals Completes Development of Proprietary Drug Delivery Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2665334536","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665334536?lang=en_us&edition=fundamental","pubTime":"2026-09-08 08:43","pubTimestamp":1788828205,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  completed the development of a proprietary single-use device for subcutaneous drug delivery aimed at both hospital use and self-administration, according to a Tuesday filing with the Australian bourse.The Zerokin device will be used to administer controlled-release formulations developed at the company's research, development and innovation center in Singapore, per the filing.Since it is intended as a Class 2 device, Zerokin will require registration for human use with the US Food and Drug Administration, and an application for CE marking under European Union regulations, the company said.It added that the global market for self-administered devices is forecast to grow to $40.5 billion by 2030 from $27.1 billion currently.Clinuvel Pharmaceuticals shares fell past 1% in recent Tuesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663040960","title":"Spotlight for Clinuvel Turning to Vitiligo Trial Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2663040960","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663040960?lang=en_us&edition=fundamental","pubTime":"2026-08-31 07:01","pubTimestamp":1788130860,"startTime":"0","endTime":"0","summary":"2300 GMT - The spotlight for Clinuvel Pharmaceuticals is increasingly turning to the readout of the CUV105 trial, says Jefferies. It is due by the end of December. Clinuvel is currently involved in a Phase 3 clinical trial of afamelanotide as a potential treatment for vitiligo, which affects some 0.75% of the U.S. population. Current treatment options are suboptimal, analyst David Stanton says. Vitiligo is a repigmentation disease with a large total addressable market of up to US$570 million in the first two years of entry to the market. \"Given Phase 2 trial results, we believe afamelanotide may eventually offer a more definitive, full-body solution than current standards of care in vitiligo,\" says Jefferies, which has a buy call on Clinuvel.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663019945","title":"Clinuvel Pharmaceuticals (ASX:CUV) Shares Undervalued Or Warning On Single Drug Risk?","url":"https://stock-news.laohu8.com/highlight/detail?id=2663019945","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663019945?lang=en_us&edition=fundamental","pubTime":"2026-08-29 06:23","pubTimestamp":1787955839,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals closed at A$8.47 after a weak few months for the stock, with the share price down over the past week, month and quarter. Yet the latest full year numbers tell a calmer story. The company delivered around A$94.0m in trailing twelve month revenue with a net profit margin near 36%. That kind of profitability is unusual in biotech and underpins a trailing P/E of 12.6x that sits well below peers.\nFor long term holders, the key point is that this remains a highly...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-shares-undervalued-or-warnin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-shares-undervalued-or-warnin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662064690","title":"Morgans Financial Downgrades Clinuvel Pharmaceuticals to Hold from Speculative Buy; Price Target is AU$10","url":"https://stock-news.laohu8.com/highlight/detail?id=2662064690","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662064690?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:43","pubTimestamp":1787913835,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) has an average rating of overweight and mean price target of AU$19.62, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic re","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CUV.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778978","title":"Clinuvel Pharmaceuticals Ltd FY Basic EPS AUD 0.68","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662778978?lang=en_us&edition=fundamental","pubTime":"2026-08-27 13:42","pubTimestamp":1787809325,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nPLX9CGWMS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662784347","title":"Press Release: a Decade of Profitability Provides Foundation for CLINUVEL's U.S. Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662784347","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662784347?lang=en_us&edition=fundamental","pubTime":"2026-08-27 13:42","pubTimestamp":1787809320,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and NEW YORK, Aug. 27, 2026  -- CLINUVEL PHARMACEUTICALS LTD  today announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 . The Company has declared a dividend of $0.05 per ordinary share.\"CLINUVEL's cash reserves following a decade of profitable operations give us financial independence in a period that has been challenging for many life science companies,\" said Mr Peter Vaughan, CLINUVEL's Group Chief Financial Officer.\"This position provides us with flexibility to pursue an expansion strategy, continue investing through market cycles in key strategic areas, and allocate capital based on opportunity rather than necessity. As CLINUVEL builds its operations and presence in the capital markets in the United States, we can do so from a position of strength.\"Key Highlights, Year Ending 30 June 2026Consolidated Entity             30 June 2026  30 June 2025  Change YOY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CUV.AU","BK7067","BK4232","BK4022","EPP","BK4582","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662722365","title":"Clinuvel Board Mulls Change to Group Structure, Potential Nasdaq Listing, ASX Delisting; Shares Dive 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662722365","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662722365?lang=en_us&edition=fundamental","pubTime":"2026-08-27 11:09","pubTimestamp":1787800165,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  said its board is considering a transaction under which the firm would change its group holding structure, seek a listing of its ordinary shares on the Nasdaq Stock Market, and delist from the ASX, according to a Thursday Australian bourse filing.It is establishing its new headquarters in the US, effective Jan. 1, 2027.Under a potential scheme of arrangement, a foreign holding company would become the new parent company of the Clinuvel, per the filing. Current shareholders of would receive ordinary shares in the holding company, representing an equivalent proportionate economic interest to their existing stake in Clinuvel. The holding company would then seek to list on the Nasdaq.The company's shares tumbled 9% in recent trading on Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CUV.AU","BK7067","LCLG","BK7508","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662240057","title":"Clinuvel Pharmaceuticals Fiscal 2026 Earnings, Revenue Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2662240057","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662240057?lang=en_us&edition=fundamental","pubTime":"2026-08-27 11:00","pubTimestamp":1787799659,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  logged AU$0.668 in EPS for fiscal 2026, compared with AU$0.718 a year ago, a Thursday filing showed.For the 12 of months June 30, revenue was AU$94 million versus AU$95 million previously, the Australia-listed pharmaceutical company added.The board declared a final dividend of AU$0.05 per share, unchanged from a year earlier, payable Sept. 18 to shareholders on record as of Sept. 4.The biopharmaceutical company's shares rose nearly 2% in recent trading on Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662272449","title":"Clinuvel Posts Fy2026 Net Profit After Tax of A$34 Million, Cash Reserves Rise to A$252 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662272449","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662272449?lang=en_us&edition=fundamental","pubTime":"2026-08-27 10:48","pubTimestamp":1787798911,"startTime":"0","endTime":"0","summary":"Clinuvel posts FY2026 net profit after tax of A$34 million, cash reserves rise to A$252 millionClinuvel posted FY2026 revenue of A$64 million, down 1%, with net profit after tax of A$34 million, down 6%.Total revenue including interest and other income reached A$101 million, down 4%.Cash reserves rose 12% to A$252 million, with net tangible assets backing per share at A$5.35, up 12%.Expenses totaled A$53 million, down 0.5%, with R&D at 34% of spending.Dividend held at A$0.05 per share, with basic earnings per share of A$0.68, down 6%.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the informa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL8sBmS8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662772468","title":"Clinuvel Pharmaceuticals - to Relocate Operational Headquarters to United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2662772468","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662772468?lang=en_us&edition=fundamental","pubTime":"2026-08-27 10:33","pubTimestamp":1787797998,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUEBKRVRG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662724680","title":"Clinuvel Pharmaceuticals - Deal Subject to Shareholder and Court Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2662724680","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662724680?lang=en_us&edition=fundamental","pubTime":"2026-08-27 10:33","pubTimestamp":1787797998,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUEBKRVRG:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662724636","title":"Clinuvel Pharmaceuticals - Shareholders to Receive Equivalent Economic Interest in NASDAQ Listed Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2662724636","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662724636?lang=en_us&edition=fundamental","pubTime":"2026-08-27 10:33","pubTimestamp":1787797998,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUEBKRVRG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CUV.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662634724","title":"Clinuvel Pharmaceuticals - Final Board Decision on Deal Pending; Due Diligence Ongoing","url":"https://stock-news.laohu8.com/highlight/detail?id=2662634724","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662634724?lang=en_us&edition=fundamental","pubTime":"2026-08-27 10:33","pubTimestamp":1787797998,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUEBKRVRG:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662372463","title":"Clinuvel Pharmaceuticals Ltd-Clinuvel Considers NASDAQ Listing, ASX Delisting","url":"https://stock-news.laohu8.com/highlight/detail?id=2662372463","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662372463?lang=en_us&edition=fundamental","pubTime":"2026-08-27 10:33","pubTimestamp":1787797998,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUEBKRVRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662243347","title":"Clinuvel Pharmaceuticals Annual Franked Dividend of A$0.05 Per Ordinary Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2662243347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662243347?lang=en_us&edition=fundamental","pubTime":"2026-08-27 10:24","pubTimestamp":1787797468,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nPLXLD0576:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","CUV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660835962","title":"Clinuvel Schedules Annual Results Investor Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2660835962","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660835962?lang=en_us&edition=fundamental","pubTime":"2026-08-20 18:08","pubTimestamp":1787220517,"startTime":"0","endTime":"0","summary":"Clinuvel schedules annual results investor webinarClinuvel schedules FY2026 results release for Aug. 27, 2026.Investor, analyst webinar set for Aug. 27, 2026, 18:00-18:30 AEST (10:00-10:30 CET).Regist","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL2slQHr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUV.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658976515","title":"Clinuvel Plans Additional Preclinical Study of VLRX-L Controlled-Release Peptide Platform in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2658976515","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658976515?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:13","pubTimestamp":1786529595,"startTime":"0","endTime":"0","summary":"Clinuvel plans additional preclinical study of VLRX-L controlled-release peptide platform in Q1 2027Clinuvel updated on VLRX-L, a controlled-release liquid injectable peptide platform, following precl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLX8KKS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658245944","title":"Clinuvel Pharmaceuticals Identifies High-Potential Dose Formulations for Injectable Peptide Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2658245944","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658245944?lang=en_us&edition=fundamental","pubTime":"2026-08-12 08:34","pubTimestamp":1786494881,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) said it identified flexible liquid dose formulations that have shown the most potential for further development as part of its VLRX-L injectable peptide formulation ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CUV.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655106845","title":"Clinuvel Pharmaceuticals Strengthens Supply Chain as Part of Commercial Preparations for North American Vitiligo Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2655106845","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655106845?lang=en_us&edition=fundamental","pubTime":"2026-07-30 09:14","pubTimestamp":1785374061,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  strengthened its supply chain, scaled up its North American infrastructure, and engaged more than 100 potential new specialty centers as part of commercial preparations for the North American vitiligo market, according to a Thursday filing with the Australian bourse.The company is developing Scenesse as the first systemic, or total body, repigmentation therapy for vitiligo, a condition that causes the loss of skin color.Scenesse adopts a different approach to treatment by targeting melanocortin receptors to stimulate the natural body process that creates pigments to color human skin, unlike JAK inhibitor therapies that suppress the immune system, the company said.Extensive vitiligo, where more than 10% of the total body surface is affected by depigmentation, currently lacks an effective therapy, Clinuvel said, adding that prior studies of Scenesse in combination with the current standard of care showed significantly improved repigmentation compared to just sta","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AFG","BK4107","CUV.AU","BK7067","BK4117","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655845588","title":"Clinuvel Benchmarks Vitiligo Market as JAK Inhibitor Efficacy Challenges Nb-uvb Standard of Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2655845588","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655845588?lang=en_us&edition=fundamental","pubTime":"2026-07-30 08:59","pubTimestamp":1785373191,"startTime":"0","endTime":"0","summary":"Clinuvel benchmarks vitiligo market as JAK inhibitor efficacy challenges NB-UVB standard of careClinuvel published a commercial update benchmarking the emerging vitiligo market against NB-UVB photothe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL37kpGW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":89,"code":"91000000","status":"200"}]}}